Circular Genomics
Circular Genomics40About
What does Circular Genomics do?
Circular Genomics is revolutionizing neurological and psychiatric care with its circular RNA platform, aiming to make brain disorders measurable and manageable. Their first product, MindLight™, is a circular RNA-based diagnostic test that predicts SSRI response in depression patients, and they are developing blood-based assays for other neurological conditions like Alzheimer's disease. The company provides actionable brain biomarker data to clinicians and payers to inform personalized treatment…
What is Circular Genomics's revenue?
StartupHub estimates Circular Genomics's annual revenue at $2.8M (range $1.6M to $5.5M, 64% confidence), based on comparable companies in the sector.
What is Circular Genomics's valuation?
StartupHub estimates Circular Genomics's effective valuation at $74.1M (range $48.8M to $117.0M, 13% confidence), based on comparable companies in the sector.
How much funding has Circular Genomics raised?
Circular Genomics has raised a total of $20M in funding. The most recent round on record is Series A.
Where is Circular Genomics headquartered?
Circular Genomics is headquartered in Jerusalem, Israel.
When was Circular Genomics founded?
Circular Genomics was founded in 2017.
What industry does Circular Genomics operate in?
Circular Genomics operates in Genomics, Biotech, HealthTech, DNA Data Storage, Sequencing Technology, Precision Medicine.
How many employees does Circular Genomics have?
Circular Genomics has approximately 18 people on record.
No comments yet. Be the first to share your take.